NASDAQ: PBLS

Parabilis Medicines (PBLS) Stock Analysis & Forecast

Oct 12 close

$28.95+1.47 (+5.3%)

Gekko Brief

AI summaryOct 12 close

Parabilis Medicines closes at $28.95, up 5.3% on the day, though shares remain down 21.5% over the past month and 7.1% over three months. The stock trades below its 50-day moving average of $35.88 and sits well off its 52-week high of $42.49, while still above the 52-week low of $24.51. The GekkoIndex reads 68.2, placing PBLS in the Accumulation zone, with the index up 0.9 over the last five sessions. Against a Gekko Fair Value of $38.28, the current price leaves a gap of -24.4%.

Looking ahead, no confirmed next earnings date is on the calendar; the last report, on 13 August 2026, showed an EPS of -2.32 against an estimate of -0.16, with a muted 0.9% price reaction. Smart money activity shows 6 open-market insider purchases totaling $6,919,552 over the past 90 days. Analyst coverage from 2 firms is unanimously bullish, with both rating the stock a buy and a consensus price target of $41.75, implying 44.2% upside from current levels. Typical daily moves of 9.4% and 20-day swings of 16.3% suggest volatility remains elevated, a factor worth noting given the stock's recent swings and the absence of a confirmed earnings catalyst in the near term.

Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.

Parabilis Medicines price vs fair value

Close $28.95Gekko Fair Value $38.28

Parabilis Medicines quick facts

Market cap: $3.37B
P/E ratio: —
Forward P/E: —
EPS, TTM: −$9.51
Revenue, TTM: $148K
Profit margin: 0%
Dividend yield: —
Beta: —
Volume: 1.20M avg 1.36M
1-year return: —
Typical daily move: ±9.4%
Typical 20-day move: ±16.3%
50-day average: $35.88
200-day average: —
Next earnings: —
Shares outstanding: 122.0M
52-week range: $24.51$42.49

Parabilis Medicines swing-trade checklist

Parabilis Medicines scores 3 supportive, 0 mixed and 0 headwinds across the 3 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive0 mixed0 headwinds

Trendno data
No data
Not enough price history for both moving averages.
See the chart
GekkoIndexsupportive
68.2, Accumulation
Reading 68.2 is in the Accumulation zone.
See the GekkoIndex
Fair valuesupportive
24.4% below
Price is 24.4% below Gekko Fair Value (more than 5% below).
See fair value
Smart moneysupportive
Leans bullish
Last 90 days: 6 open-market insider purchases.
See smart money
Earnings riskno data
No data
No confirmed report date on the calendar.
See earnings
Seasonalityno data
No data
Not enough years of history for a seasonal read.

A description of current data, not a recommendation. How this page works

Parabilis Medicines stock chart and price history

Parabilis Medicines closed at $28.95 on Oct 12, 2026, inside a 52-week range of $24.51 to $42.49.

5Y and weekly in Gekko

Close50-day average200-day averageVolume

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month: −21.5%
3 months: −7.1%

The full PBLS chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PBLS in Gekko

Follow Parabilis Medicines through every session

Put PBLS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track PBLS in GekkoFree for 7 days. No credit card required.

About Parabilis Medicines

Parabilis Medicines is a clinical-stage pharmaceutical company focused on cancer treatment. Its work centers on cell-penetrating miniproteins, a class of molecules engineered to enter cancer cells and disable the proteins inside them that drive tumor growth. This approach to neutralizing cancer-causing proteins from within the cell is the core of what the company is known for.

The company's efforts are organized around research and development rather than commercial sales, as is typical for a business still in the clinical stage. Its activity centers on advancing its miniprotein-based therapies through the stages needed to bring new cancer treatments closer to patients, rather than generating revenue from an existing product line.

Parabilis Medicines was founded in 2015 by Gregory L. Verdine, WeiQing Zhou and David Philip Lane, and it is headquartered in Cambridge, Massachusetts. Its shares are listed on the NASDAQ under the ticker PBLS.

Listed: NASDAQ
Sector: Health technology
Website: parabilismed.com

Parabilis Medicines GekkoIndex: the smart money zone

Parabilis Medicines’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 68.2, in the Accumulation zone, up 0.9 points over five sessions.

68.2Accumulation

Up 0.9 points over five sessions.

Reading for Oct 12, 2026

What followed past readings in each zone

Zone	Readings	5 days	10 days	20 days	50 days
Buying	6	Too few readings yet
Accumulation (current zone)	20	−0.4%	−0.8%	+11.4%	+37.0%
Neutral	52	+0.6%	+1.9%	+4.9%	+10.0%
Distribution	1	Too few readings yet
Selling	1	Too few readings yet

Average PBLS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.

Selling<33

Distribution33–45

Neutral45–60

Accumulation60–70

Buying70+

Accumulation zone: Institutional interest building. About the five zones →

See every daily GekkoIndex reading plotted over the PBLS price, zone by zone.Track PBLS in Gekko

Is Parabilis Medicines stock overvalued? Gekko Fair Value

Parabilis Medicines trades 24.4% below Gekko Fair Value of $38.28, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Parabilis Medicines shares are worth, recalculated every trading day.

$38.28

Gekko Fair Value, Oct 10, 2026

24.4% Undervalued

Price$28.95

Gekko Fair Value$38.28

At the end of Aug 2026 the price was 0.7% above the estimate.

Gekko Fair ValueShare price, month end

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open PBLS in Gekko

Parabilis Medicines insider and Congress trading

Insiders filed 6 open-market purchases in Parabilis Medicines worth $6.92M, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$6.92Min 6 open-market purchases

Filed	Insider	Type	Shares	Value
Jul 22	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah Director, 10% Owner	Purchase	98,433	$2.67M
Jul 22	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah Director, 10% Owner	Purchase	47,250	$1.41M
Jul 22	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah Director, 10% Owner	Purchase	37,723	$1.13M
Jul 22	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah Director, 10% Owner	Purchase	32,987	$914K
Jul 22	RA CAPITAL MANAGEMENT, L.P. / RA Capital Healthcare Fund LP / RA Capital Nexus Fund III, L.P. / Peter Kolchinsky / Rajeev M. Shah Director, 10% Owner	Purchase	21,696	$607K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in PBLS were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for PBLS, plotted on the chart in Gekko.Open PBLS in Gekko

Parabilis Medicines earnings: next date and track record

Parabilis Medicines beat the EPS estimate in 0 of its last 1 report, moving 0.9% on average across the report.

0 of 1reports beat the EPS estimate

±0.9%average move across the report

0 of 1reports followed by a gain

Reported	EPS	Surprise	Revenue	Surprise	Move
Aug 13, 2026	−$2.32 est −$0.16	−1,306.1%	$100K est $16.67M	−99.4%	−0.9%
May 19, 2026	−$0.72	—	—	—	—

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Parabilis Medicines stock forecast and analyst price targets

Analysts’ average 12-month price target for Parabilis Medicines is $41.75, +44.2% from the last close, from 2 firms rating the stock in the last 90 days.

$41.75consensus 12-month target, +44.2% from the last close

Now $28.95Avg $41.75

Low $42High $45

Buy2

Hold0

Sell0

Each firm’s latest rating in the last 90 days: 2 firms.

Latest analyst actions

Date	Firm	Rating	Target	vs price
Sep 16	Bank of America Securities	Buy, maintained	$45	+55.4%
Aug 14	Bank of America Securities	Buy, maintained	—	—
Aug 13	LifeSci Capital	Buy, maintained	$42	+45.1%
Jul 18	LifeSci Capital	Buy, initiated	$42	+45.1%

+11.4%average 20-day move after past Accumulation readings

±9.4%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Parabilis Medicines market cap and key statistics

Parabilis Medicines’s market cap is $3.37B and revenue of $148K over the last twelve months.

Valuation

Market cap: $3.37B
EPS, TTM: −$9.51
Gekko Fair Value: $38.28

Trading

Volume: 1.20M
Avg volume, 20 days: 1.36M
52-week high: $42.49
52-week low: $24.51
Shares outstanding: 122.0M

Financials

Revenue, TTM: $148K
Profit margin: 0%
Return on equity: 0%
Quarterly earnings growth, YoY: 0.0%

Risk and income

Typical daily move: ±9.4%
Typical 20-day move: ±16.3%

More stocks

Parabilis Medicines stock FAQ

What is Parabilis Medicines’s market cap?

Parabilis Medicines’s market cap is $3.37B at the Oct 12, 2026 close of $28.95, with 122.0M shares outstanding.

What is the Parabilis Medicines stock forecast?

The consensus analyst 12-month price target for Parabilis Medicines is $41.75, +44.2% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Parabilis Medicines stock overvalued or undervalued?

On Gekko’s estimate Parabilis Medicines is undervalued: the Oct 12, 2026 close of $28.95 is 24.4% below Gekko Fair Value of $38.28. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

What is Parabilis Medicines’s 52-week high and low?

Parabilis Medicines’s 52-week high is $42.49 and its 52-week low is $24.51; it closed at $28.95 on Oct 12, 2026.

Is Parabilis Medicines stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 3 items with data read as supportive (gekkoindex, fair value and smart money). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

Built and overseen by Jared Mann

Founder of Gekko.app. Jared has traded stocks and ETFs for more than 20 years and has a financial industry background.

About Gekko How Gekko’s data works Report an error

See Parabilis Medicines the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,408 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.